Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market
Mandate

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market

April 29, 2022 Capital Markets and Public M&A

Vinge has advised Promimic AB (publ) in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 29 April 2022. In connection with the listing, a shares subscription offer was performed at a subscription price of SEK 16.

Promimic AB is a biomaterials company which produces and markets HAnano Surface, a unique coating for medical implants which strengthens their anchoring in bone tissue. Promimic focuses on the dental and orthopaedic implant market.

Vinge’s team consisted primarily of Anders Strid, Johanna Hamrefält (project manager), Adrian Filipovic, Rebecka Hansson, Anna Högsten and Fredrik Löwenclou.

 

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026